INS and metabolic dysfunction-associated steatotic liver disease: In the state of insulin resistance in NAFLD, insulin is unable to suppress the hepatic glucose production with the worsening of the glycemic control, and at the same time lipogenesis continues, further contributing to the atherogenic lipid profile in NAFLD with increased risk of cardiovascular complications (118–121).